Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Assets (2020 - 2025)

Historic Current Assets for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $184.1 million.

  • Foghorn Therapeutics' Current Assets fell 3211.88% to $184.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.1 million, marking a year-over-year decrease of 3211.88%. This contributed to the annual value of $249.6 million for FY2024, which is 392.2% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Current Assets stood at $184.1 million for Q3 2025, which was down 3211.88% from $203.8 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Current Assets high stood at $459.6 million for Q4 2021, and its period low was $124.0 million during Q3 2021.
  • Moreover, its 5-year median value for Current Assets was $265.4 million (2023), whereas its average is $273.9 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Current Assets skyrocketed by 20476.07% in 2022, and later tumbled by 3404.41% in 2024.
  • Foghorn Therapeutics' Current Assets (Quarter) stood at $459.6 million in 2021, then decreased by 23.54% to $351.4 million in 2022, then tumbled by 31.65% to $240.2 million in 2023, then increased by 3.92% to $249.6 million in 2024, then fell by 26.24% to $184.1 million in 2025.
  • Its Current Assets was $184.1 million in Q3 2025, compared to $203.8 million in Q2 2025 and $225.4 million in Q1 2025.